Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients

Author:

Hein Alexander,Gass Paul,Walter Christina Barbara,Taran Florin-Andrei,Hartkopf Andreas,Overkamp Friedrich,Kolberg Hans-Christian,Hadji Peyman,Tesch Hans,Ettl Johannes,Wuerstlein Rachel,Lounsbury Debra,Lux Michael P.,Lüftner Diana,Wallwiener Markus,Müller Volkmar,Belleville Erik,Janni Wolfgang,Fehm Tanja N.,Wallwiener Diethelm,Ganslandt Thomas,Ruebner Matthias,Beckmann Matthias W.,Schneeweiss Andreas,Fasching Peter A.,Brucker Sara Y.

Funder

Federal Ministry of Economic Affairs and Energy

Novartis

Pfizer

BioMarin Pharmaceutical Inc.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Reference21 articles.

1. Schmidt M, Fasching PA, Beckmann MW, Kolbl H (2012) Biomarkers in breast cancer—an update. Geburtshilfe Frauenheilkd 72(9):819–832. doi: 10.1055/s-0032-1315340

2. Fasching PA, Ekici AB, Wachter DL, Hein A, Bayer CM, Haberle L, Loehberg CR, Schneider M, Jud SM, Heusinger K, Rubner M, Rauh C, Bani MR, Lux MP, Schulz-Wendtland R, Hartmann A, Beckmann MW (2013) Breast cancer risk—from genetics to molecular understanding of pathogenesis. Geburtshilfe Frauenheilkd 73(12):1228–1235. doi: 10.1055/s-0033-1360178

3. von Minckwitz G, Loibl S, Schneeweiss A, Salat CT, Rezai M, Zahm DM, Klare P, Blohmer JU, Tesch H, Khandan F, Fasching PA, Jakisch C, Nekljudova V, Untch M (2015) Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto) Cancer Res 76(4 Suppl):Abstract nr S2-04. (76(4 Suppl)):Abstract nr S2-04

4. ClinicalTrials.gov (2016) Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA). https://clinicaltrials.gov/ct2/show/NCT02032823 Accessed on 10 Mar 2016

5. ClinicalTrials.gov (2016) A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA). https://clinicaltrials.gov/ct2/show/NCT01945775 Accessed on 10 Mar 2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3